Progress in molecular resistance mechanisms of targeted therapy for chronic myeloid leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 73-76, 2022.
Article
en Zh
| WPRIM
| ID: wpr-929736
Biblioteca responsable:
WPRO
ABSTRACT
Resistance or drug-resistant recurrence of targeted tumor therapy is a complex and multi-factorial process, with the final result of tumor clones that can evade treatment or have relative proliferation advantages under treatment pressure being selectively retained. The BCR::ABL1 fusion gene is the primary molecular abnormality of chronic myeloid leukemia (CML), and the development and application of tyrosine kinase inhibitors (TKI) targeting the BCR::ABL1 fusion protein pioneered the era of small molecule targeted therapeutics. Several TKI have been approved for clinical application or in development. Although most CML patients manifest an excellent response to TKI treatment, there are still some patients with poor primary response or relapse with drug resistance. With the increase in the number of patients with long-term maintenance therapy and the sequential use of multiple TKI, the resistance of TKI has become more complicated. This article introduces the research progress of CML molecular resistance mechanisms in recent years and shares the relevant cutting-edge reports at the 63rd American Society of Hematology Annual Meeting in 2021.
Texto completo:
1
Base de datos:
WPRIM
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Año:
2022
Tipo del documento:
Article